Novel IDH1/2 Inhibitor Shows ‘Dramatic Effect’ in Low-Grade Glioma
CHICAGO — Oral vorasidenib monotherapy significantly improved progression-free survival (PFS), and delayed the time to next therapy, in patients with mutated, low-grade glioma, according to an interim analysis of the INDIGO trial. Among 331 patients with grade 2 isocitrate dehydrogenase (IDH)-mutant glioma, who received no prior treatment other than surgery, those randomly assigned to receive […]
Pembrolizumab Active in BCG-Unresponsive Papillary High-Risk Bladder Cancer
SAN FRANCISCO — Pembrolizumab (Keytruda) monotherapy showed encouraging antitumor activity in patients with papillary high-risk non-muscle-invasive bladder cancer (HR NMIBC) that was unresponsive to Bacillus Calmette-Guerin (BCG) treatment. In a cohort of patients in the KEYNOTE-057 study who had 45 months of follow-up, those treated with pembrolizumab (n=32) had an estimated 12-month disease-free survival (DFS) […]
Xtandi During AS Reduced Progression Risk in Early Prostate Cancer
Patients with low- or intermediate-risk localized prostate cancer who received enzalutamide (Xtandi) monotherapy saw a reduced risk of cancer progression, according to a randomized phase II trial. Among 227 patients on active surveillance (AS), treatment with enzalutamide reduced the risk of pathological or therapeutic prostate cancer progression by 46% compared with AS alone (HR 0.54, […]